Log In
BCIQ
Print this Print this
 

SER140

  Manage Alerts
Collapse Summary General Information
Company Serodus ASA
DescriptionIL-1 receptor antagonist
Molecular Target Interleukin-1 (IL-1) receptor
Mechanism of ActionInterleukin-1 (IL-1) receptor antagonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$0.7M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/15/2013

$0.7M

0

0

Get a free BioCentury trial today